Pancreatic Cancer Research

ResearcherOspedale P. Pederzoli – Casa di Cura Privata S.p.a.Active in the last 2 years

Filippo Scopelliti

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5539-6653; OpenAlex author ID A5022418634. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
37
Papers, trials and grants by year

2017: 2 papers · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 9

  1. The Role of a "Conservative" Resection Strategy After Neoadjuvant Treatment for Borderline/Locally Advanced PDAC with Arterial Involvement: A Single-Centre Ret… Co-author DOI 10.3390/cancers18050830↗
  2. Bayesan Model to Predict R Status After Neoadjuvant Therapy in Pancreatic Cancer. Co-author DOI 10.3390/cancers16234106↗
  3. Prognostic value of major pathological response following neoadjuvant therapy for non resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2023.02.005↗
  4. Prognostic Factors After Pancreatectomy for Pancreatic Cancer Initially Metastatic to the Liver. Co-author DOI 10.1245/s10434-022-12385-4↗
  5. Open radiofrequency ablation as upfront treatment for locally advanced pancreatic cancer: Requiem from a randomized controlled trial. Co-author DOI 10.1016/j.pan.2021.06.005↗
  6. A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial. Co-author DOI 10.1177/1758835920947969↗
  7. Technique, safety, and feasibility of EUS-guided radiofrequency ablation in unresectable pancreatic cancer. Co-author DOI 10.1007/s00464-018-6217-x↗
  8. Immunomodulation after radiofrequency ablation of locally advanced pancreatic cancer by monitoring the immune response in 10 patients. Co-author DOI 10.1016/j.pan.2017.09.008↗
  9. Downstaging in Stage IV Pancreatic Cancer: A New Population Eligible for Surgery? Co-author DOI 10.1245/s10434-017-5885-4↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Paolo Regi · 9 shared papers, 2017–2026 · strength 1.10
  2. Alessandro Giardino · 9 shared papers, 2017–2026 · strength 1.10
  3. Isabella M. Frigerio · 9 shared papers, 2017–2026 · strength 1.10
  4. Giovanni Butturini · 9 shared papers, 2017–2026 · strength 1.10
  5. Roberto Girelli · 8 shared papers, 2017–2026 · strength 1.03
  6. Claudio Bassi · 5 shared papers, 2017–2022 · strength 0.43
  7. Giuseppe Malleo · 4 shared papers, 2017–2022 · strength 0.36
  8. Gaya Spolverato · 2 shared papers, 2023–2024 · strength 0.35
  9. Quoc Riccardo Bao · 2 shared papers, 2023–2024 · strength 0.35
  10. Paolo Pederzoli · 2 shared papers, 2018–2026 · strength 0.33
  11. Roberto Salvia · 3 shared papers, 2020–2022 · strength 0.31
  12. Erica Pizzocaro · 1 shared paper, 2026 · strength 0.25
  13. Roberta Vella · 1 shared paper, 2026 · strength 0.25
  14. Salvatore Paiella · 3 shared papers, 2017–2021 · strength 0.23
  15. Mirko D’Onofrio · 3 shared papers, 2017–2021 · strength 0.23
  16. Alessandro Esposito · 2 shared papers, 2020–2022 · strength 0.21
  17. Darío Gregori · 1 shared paper, 2024 · strength 0.19
  18. Michèle Milella · 2 shared papers, 2020–2021 · strength 0.17
  19. Marzia Tripepi · 1 shared paper, 2023 · strength 0.16
  20. Matteo De Pastena · 1 shared paper, 2022 · strength 0.13
  21. Paola Capelli · 2 shared papers, 2017–2020 · strength 0.13
  22. Andrea Mambrini · 1 shared paper, 2021 · strength 0.10
  23. Maurizio Cantore · 1 shared paper, 2021 · strength 0.10
  24. Giammaria Fiorentini · 1 shared paper, 2021 · strength 0.10
  25. Alessandro Passardi · 1 shared paper, 2021 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.